High PIB Retention in Alzheimer's Disease is an Early Event with Complex Relationship with CSF Biomarkers and Functional Parameters

被引:78
作者
Forsberg, A.
Almkvist, O. [2 ,9 ]
Engler, H. [3 ,4 ,5 ,6 ]
Wall, A. [7 ]
Langstrom, B. [8 ]
Nordberg, A. [1 ,2 ]
机构
[1] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Alzheimer Neurobiol, S-14186 Stockholm, Sweden
[2] Karolinska Univ Hosp Huddinge, Dept Geriatr Med, S-14186 Stockholm, Sweden
[3] Univ Uppsala Hosp, Dept Nucl Med, Uppsala, Sweden
[4] Univ Republica, Univ Hosp Clin, Dept Nucl Med, Montevideo, Uruguay
[5] Univ Republica, Nucl Res Ctr, Montevideo, Uruguay
[6] Uruguayan Ctr Mol Imaging, Montevideo, Uruguay
[7] GE Healthcare, Uppsala Imanet AB, Uppsala, Sweden
[8] Uppsala Univ, Dept Biochem & Organ Chem, Uppsala, Sweden
[9] Stockholm Univ, Dept Psychol, S-10691 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
Amyloid; CSF biomarkers; C-11-PIB-PET; F-18-FDG-PET; AD; MCI; cognition; MILD COGNITIVE IMPAIRMENT; PITTSBURGH COMPOUND-B; POSITRON-EMISSION-TOMOGRAPHY; PET AMYLOID LIGAND; CEREBROSPINAL-FLUID; PARKINSONS-DISEASE; GLUCOSE-METABOLISM; C-11-PIB PET; NONDEMENTED INDIVIDUALS; PHOSPHORYLATED-TAU;
D O I
10.2174/156720510790274446
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: New in vivo amyloid PET imaging tracers, such as C-11-PIB, provide possibilities to deeper understand the underlying pathological processes in Alzheimer's disease (AD). In this study we investigated how C-11-PIB retention is related to cerebral glucose metabolism, episodic memory and CSF biomarkers. Method: Thirty-seven patients with mild AD and 21 patients with mild cognitive impairment (MCI) underwent PET examinations with the amyloid tracer C-11-PIB, F-18-FDG for measurement of regional cerebral metabolic rate of glucose (rCMRglc), assessment of episodic memory and assay of cerebral spinal fluid (CSF) levels of amyloid-beta (A beta(1-42)), total tau and phosphorylated tau respectively. Analyses were performed using Statistical Parametric Mapping (SPM) and regions of interest (ROIs). Results: Pooled data from AD and MCI patients showed strong correlations between C-11-PIB retention, levels of CSF biomarkers (especially A beta(1-42)), rCMRglc and episodic memory. Analysis of the MCI group alone revealed significant correlations between C-11-PIB retention and CSF biomarkers and between CSF biomarkers and episodic memory respectively. A strong correlation was observed in the AD group between rCMRglc and episodic memory as well as a significant correlation between C-11-PIB retention and rCMRglc in some cortical regions. Regional differences were observed as sign for changes in temporal patterns across brain regions. Conclusions: A complex pattern was observed between pathological and functional markers with respect to disease stage (MCI versus AD) and brain regions. Regional differences over time were evident during disease progression. C-11-PIB PET and CSF A beta(1-42) allowed detection of prodromal stages of AD. Amyloid imaging is useful for early diagnosis and evaluation of new therapeutic interventions in AD.
引用
收藏
页码:56 / 66
页数:11
相关论文
共 74 条
[1]   Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly [J].
Aizenstein, Howard Jay ;
Nebes, Robert D. ;
Saxton, Judith A. ;
Price, Julie C. ;
Mathis, Chester A. ;
Tsopelas, Nicholas D. ;
Ziolko, Scott K. ;
James, Jeffrey A. ;
Snitz, Beth E. ;
Houck, Patricia R. ;
Bi, Wenzhu ;
Cohen, Ann D. ;
Lopresti, Brian J. ;
DeKosky, Steven T. ;
Halligan, Edythe M. ;
Klunk, William E. .
ARCHIVES OF NEUROLOGY, 2008, 65 (11) :1509-1517
[2]   Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies [J].
Alexander, GE ;
Chen, K ;
Pietrini, P ;
Rapoport, SI ;
Reiman, EM .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (05) :738-745
[3]  
Almkvist O, 1996, ACTA NEUROL SCAND, V93, P63
[4]   Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease [J].
Anchisi, D ;
Borroni, B ;
Franceschi, M ;
Kerrouche, N ;
Kalbe, E ;
Beuthien-Beumann, B ;
Cappa, S ;
Lenz, O ;
Ludecke, S ;
Marcone, A ;
Mielke, R ;
Ortelli, P ;
Padovani, A ;
Pelati, O ;
Pupi, A ;
Scarpini, E ;
Weisenbach, S ;
Herholz, K ;
Salmon, E ;
Holthoff, V ;
Sorbi, S ;
Fazio, F ;
Perani, D .
ARCHIVES OF NEUROLOGY, 2005, 62 (11) :1728-1733
[5]   Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].
Andreasen, N ;
Hesse, C ;
Davidsson, P ;
Minthon, L ;
Wallin, A ;
Winblad, B ;
Vanderstichele, H ;
Vanmechelen, E ;
Blennow, K .
ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680
[6]   CSF markers for incipient Alzheimer's disease [J].
Blennow, K ;
Hampel, H .
LANCET NEUROLOGY, 2003, 2 (10) :605-613
[7]   tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease? [J].
Blennow, K ;
Wallin, A ;
Agren, H ;
Spenger, C ;
Siegfried, J ;
Vanmechelen, E .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) :231-245
[8]   Longitudinal stability of CSF biomarkers in Alzheimer's disease [J].
Blennow, Kaj ;
Zetterberg, Henrik ;
Minthon, Lennart ;
Lannfelt, Lars ;
Strid, Stig ;
Annas, Peter ;
Basun, Hans ;
Andreasen, Niels .
NEUROSCIENCE LETTERS, 2007, 419 (01) :18-22
[9]   Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment [J].
Brys, Miroslaw ;
Pirraglia, Elizabeth ;
Rich, Kenneth ;
Rolstad, Sindre ;
Mosconi, Lisa ;
Switalski, Remigiusz ;
Glodzik-Sobanska, Lidia ;
De Santi, Susan ;
Zinkowski, Ray ;
Mehta, Pankaj ;
Pratico, Domenico ;
Saint Louis, Leslie A. ;
Wallin, Anders ;
Blennow, Kaj ;
de Leon, Mony J. .
NEUROBIOLOGY OF AGING, 2009, 30 (05) :682-690
[10]   Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment [J].
Buerger, K ;
Teipel, SJ ;
Zinkowski, R ;
Sunderland, T ;
Andreasen, N ;
Blennow, K ;
Ewers, M ;
DeBernardis, J ;
Shen, Y ;
Kerkman, D ;
Du, YS ;
Hampel, H .
NEUROSCIENCE LETTERS, 2005, 391 (1-2) :48-50